Pegvisomant
Growth Hormone Receptor Antagonist — SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS
Also known as: B-2036 PEG, B2036-PEG, pegvisomant (genetical recombination), somavert, trovert
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Pegvisomant is a drug in the Growth Hormone Receptor Antagonist class catalogued in DrugCentral. It was first approved by the EMA in 2002. Its mechanism of action is classified as Growth Hormone Receptor Antagonists. DrugCentral lists 1 molecular target, including GHR. Recorded indications include Acromegaly.
- Drug class: Growth Hormone Receptor Antagonist.
- Mechanism of action: Growth Hormone Receptor Antagonists.
- Molecular targets: GHR (1 listed in DrugCentral).
- Indications: Acromegaly.
- ATC code: H01AX01 (Other anterior pituitary lobe hormones and analogues).
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Acromegaly
Mechanism & targets
| Mechanism of action (MoA) | Growth Hormone Receptor Antagonists |
|---|---|
| Established pharmacologic class | Growth Hormone Receptor Antagonist |
Molecular targets (1)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Growth hormone receptor | GHR | antagonist | — |
Regulatory approvals (2)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2003-03-25 | FDA | — | PHARMACIA AND UPJOHN | Yes |
| 2002-11-13 | EMA | — | — |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
H01AX01 | SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS › PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES › ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES › Other anterior pituitary lobe hormones and analogues |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Insulin-like growth factor increased | 1536.7 |
| Blood growth hormone increased | 494.9 |
| Needle issue | 375.1 |
| Insulin-like growth factor abnormal | 205.6 |
| Pituitary tumour | 185.3 |
| Injection site pain | 178.2 |
| Insulin-like growth factor decreased | 162.4 |
| Lipohypertrophy | 157.9 |
| Pituitary tumour benign | 139.5 |
| Injection site bruising | 137.1 |
| Injection site mass | 130.0 |
| Product dose omission issue | 129.5 |
Chemical structure
| Molecular formula | — |
|---|---|
| Molecular weight | — |
| CAS number | — |
| InChIKey | — |
| PubChem CID | — |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Pegvisomant used for?
DrugCentral lists the following indications for Pegvisomant: Acromegaly.
How does Pegvisomant work?
Pegvisomant is classified as Growth Hormone Receptor Antagonists; its molecular targets in DrugCentral include GHR (antagonist).
When was Pegvisomant first approved?
Pegvisomant was first approved by the EMA in 2002.
What drug class does Pegvisomant belong to?
Pegvisomant is in the Growth Hormone Receptor Antagonist class.
Browse: all drugs starting with P · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5015 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL1201515 — compound record and bioactivity
- DrugBank DB00082 — drug record
- FDA UNII N824AOU5XV — substance identity
- DailyMed: FDA labels for Pegvisomant — current prescribing information (label search)
- UniProt P10912 (GHR) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.